Data from these studies were summarized in a meta-analysis, which showed that patients who had HER2+ breast cancer and were treated with Trastuzumab had approximately a 50% reduction in the risk of early recurrence and mortality, irrespective of nodal status [10]. Here, ERBB2 is linked to breast cancer.